ORPHA:765
Pyruvate dehydrogenase deficiency
Also known as: PDH · PDHC · Pyruvate dehydrogenase complex deficiency
Publications
1,318
Trials
4
Interventional, condition-specific
Researchers
1,215
Distinct authors in sample
Gene link
—
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
Pyruvate dehydrogenase deficiency (PDHD) is a rare neurometabolic disorder characterized by a wide range of clinical signs with and neurological components of varying severity. Manifestations range from often fatal, severe, lactic to later-onset neurological disorders. Six subtypes related to the affected subunit of the PDH complex have been recognized with significant clinical overlap: PDHD due to E1-alpha, E1-beta, E2 and E3 deficiency, PDHD due to E3-binding protein deficiency, and PDH phosphatase deficiency.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019169
- UMLS:C0034345
- NCIT:C103968
Additional Mondo synonyms (4)
Pyruvate Dehydrogenase Complex Deficiency · pyruvate decarboxylase deficiency · pyruvate dehydrogenase complex deficiency · pyruvate dehydrogenase deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,318 matched papers (620 in last 10 years) Source
- Phenotype characterisedPresent
365 HPO annotations (e.g. Neurodevelopmental delay; Feeding difficulties; Microcephaly) Source
- Animal modelPresent
2 genotype models (Danio rerio) Source
- Orphan designationPartial
1 EMA designation (none yet with FDA orphan-indication approval) — e.g. sodium phenylbutyrate Source
- Interventional trialPresent
4 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
365
Associated phenotypes · MONDO:0019169
- Neurodevelopmental delay
- Feeding difficulties
- Microcephaly
- Hyperammonemia
- Muscle spasm
Showing 5 of 365 — open Monarch for the full list.
Animal models (Monarch / Alliance)
2
Model associations linked to this Mondo ID
- dlata13/a13 (AB)·ZFIN:ZDB-FISH-150901-7269·Danio rerio
- dlatm631/m631·ZFIN:ZDB-FISH-160608-1·Danio rerio
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · no FDA orphan-indication approval yet
- EMA sodium phenylbutyrateTreatment of pyruvate dehydrogenase complex deficiency · 11/11/2015 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
4
Drugs / clinical candidates · MONDO_0019169
- DICHLOROACETIC ACID·phase 3
- GLYCEROL PHENYLBUTYRATE·phase 2
- SODIUM PHENYLBUTYRATE·phase 2
- TRIHEPTANOIN·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,318
1,318 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,318 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
620 in the last 10 years · low confidence
Phrase hits: 1,318 · MeSH hits: 0
Who's working on it?
1,215
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li X4 papers · 2026
Pediatric Neurology, Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Papers in Europe PMC - 02Rivera I4 papers · 2026
Research Institute for Medicines (iMed.ULisboa) and Department of Biochemistry and Human Biology, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal. Electronic address: iarivera@ff.ulisboa.pt.
Papers in Europe PMC - 03Alves C3 papers · 2025
Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Papers in Europe PMC - 04Bedoyan JK3 papers · 2024
Departments of Genetics and Genome Sciences Case Western Reserve University (CWRU) Cleveland Ohio USA.
Papers in Europe PMC - 05Boutron A3 papers · 2016
Department of Biochemistry, Hospital Bicêtre, Le Kremlin Bicêtre, France.
Papers in Europe PMC - 06Darin N3 papers · 2026
Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Papers in Europe PMC - 07De Lonlay P3 papers · 2026
Reference Center of Inherited Metabolic Diseases, University Paris Descartes, Hospital Necker Enfants Malades, APHP, Paris, France. Electronic address: pascale.delonlay@nck.aphp.fr.
Papers in Europe PMC - 08Eklund EA3 papers · 2026
Section for Pediatrics, Department of Clinical Sciences, Lund University, Lund, Sweden.
Papers in Europe PMC - 09Falk MJ3 papers · 2026
Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Papers in Europe PMC - 10Florindo C3 papers · 2023
Research Institute for Medicines (iMed.ULisboa) and Department of Biochemistry and Human Biology, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
4
interventional trials for this specific condition
4 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026
4 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 88.1th percentile).
low confidence · 88.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
4 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06340685·RECRUITING·Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
Not reviewed·Conditions: Pyruvate Dehydrogenase Complex Deficiency·Matched via name phrase
- NCT06887777·RECRUITING·Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)
Not reviewed·Conditions: Pyruvate Dehydrogenase Complex Deficiency Disease·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03056794·RECRUITING·Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies
Not reviewed·Conditions: Pyruvate Dehydrogenase Complex Deficiency Disease·Matched via name phrase
General rare disease registries you may be eligible for
These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.
- NCT01793168·RECRUITING·Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Not reviewed·Conditions: Rare Disorders · Undiagnosed Disorders · Disorders of Unknown Prevalence · Cornelia De Lange Syndrome
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- ctis·2024-516410-38-00·Authorised, ongoing·PDH-RAVICTI - A PHASE II, MULTICENTRIC, PROSPECTIVE, NON-COMPARATIVE CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF THE TREATMENT OF PYRUVATE DEHYDROGENASE DEFICIENCY (PDH) PATIENTS WITH GLYCEROL PHENYLBUTYRATE (RAVICTI®)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN96463686·No longer recruiting·An online psychoeducational and support program implementing ketogenic metabolic therapy for mental illness
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pyruvate dehydrogenase deficiency — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Pyruvate dehydrogenase deficiency" OR "Pyruvate dehydrogenase complex deficiency" OR "pyruvate decarboxylase deficiency"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pyruvate dehydrogenase deficiency" OR "Pyruvate dehydrogenase complex deficiency" OR "pyruvate decarboxylase deficiency"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 4 interventional · 2 observational · 1 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PDH; PDHC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- "pyruvate decarboxylase deficiency" also appears on ORPHA:79243
- Publication count (1318) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T15:16:22.150Z
